ECB Calls for Monitoring and Possible Regulation of AI in Finance 
Why banks consider renewable energy to be a riskier investment than fossil fuels 
BYD Launches Shark Hybrid Pickup in Mexico, Eyes New Factory Amid US Tariff Hike 
McDonald's Philippines Launches 'Ride the Arches' for Cyclists 
PUMA Welcomes AC Milan Star Theo Hernández to the Family 
Burger King’s Largest Franchisee Carrols, Acquired by RBI for $1 Billion, $500M Revamp 
Semaglutide's Benefits Beyond Weight Loss: New Insights from the SELECT Trial 
How supermarkets are changing their branding to make you think they’re cheaper 
Skechers Sales Surge as Growth Lags for Nike and Adidas; Nike Eyes 2024 Olympics 
Dolly Parton Serves Up Sweetness with Krispy Kreme Collaboration 
Shein's Potential London IPO Could Revitalize LSE Amid Geopolitical Tensions 
Coca-Cola Launches Data-Driven Insights Platform for Retail and Foodservice Industries 
McDonald’s Rolls Out $5 Meal Deals to Emphasize Affordability Amid Rising Costs 
Converse Faces Job Cuts as Nike Aims for $2 Billion in Cost Savings 
The 2023 Sir Paul Curran award for academic journalism goes to Barbara Sahakian 
DURHAM, N.C., March 29, 2016 -- In the release issued earlier today by Argos Therapeutics (Nasdaq:ARGS), please note that the "Selected Third Quarter 2015 Financial Results" header should be "Selected Fourth Quarter and Full-Year 2015 Financial Results." All other information in the press release remains the same.
Media contacts: Adam Daley Berry & Company Public Relations 212-253-8881 [email protected] Investor contact: John Menditto Argos Therapeutics, Inc. 919-908-0687 [email protected]
